APAC CIO Outlook
  • Home
  • CXO Insights
  • CIO Views
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • About us
Apac
  • Admired Tech

    Agile

    AI Healthcare

    Artificial Intelligence

    Augmented Reality

    Aviation

    Big Data

    Blockchain

    Cloud

    Cryptocurrency

    Cyber Security

    Digital Transformation

    Drone

    HPC

    Infrared

    Internet of Things

    Networking

    PropTech

    Remote Work

    Scheduling Software

    Simulation

    Startup

    Storage

    Wireless

  • Banking

    E-Commerce

    Education

    FinTech

    Food and Beverages

    Healthcare

    Insurance

    Legal

    Manufacturing

    Pharma and Life Science

    Retail

    Travel and Hospitality

  • Atlassian

    CISCO

    Microsoft

    Oracle

    Salesforce

    SAP

    ServiceNow

  • Business Intelligence

    CEM

    Cloud-based Planning

    Cognitive

    Compliance

    Contact Center

    Contact Tracing

    Contactless Payments

    Content Management System

    Corporate Finance

    CRM

    Custom Software Development

    Data Center

    Enterprise Architecture

    Enterprise Communications

    Enterprise Contract Management

    ERP

    Field Service

    HR Technology

    IT Service Management

    Managed Services

    Procurement

    Product Management

    RegTech

    Revenue Management

    Sales Tech

Menu
    • Augmented Reality
    • Agile
    • Cognitive
    • Cyber Security
    • Digital Transformation
    • Atlassian
    • E-Commerce
    • Managed Services
    • RegTech
    • CISCO
    • Blockchain
    • IoT
    • MORE
    #

    Apac CIO Outlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIO Outlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • News
    • Pharma and Life Science
    Editor's Pick (1 - 4 of 8)
    left
    The 4Ps of Digital Transformation in Pharmaceutical Industry

    Debraj Dasgupta, Operating Officer, Head of Strategy and Go-To-Market Planning Division, Nippon Boehringer Ingelheim

    Cloud Computing: Pharma Takes the Plunge

    Andy Newsom, SVP & CIO, CSL Behring

    Machine Learning & Artificial Intelligence in Healthcare Industry

    James Woo, CIO, The Farrer Park Company

    Connected Patients: Healthcare and the Internet of Things

    Geoff Feakes, Group CIO, Tunstall Healthcare Group

    Building a Quality-Focused IT Foundation for a Biopharmaceutical Enterprise

    Andy Newsom, SVP, CIO, CSL Behring

    Points of Focus for CIOs to Succeed in the Next Decade and Beyond

    Dr. Joseph Frassica, CMIO/CTO, Patient Care and Monitoring Solutions, Philips Healthcare

    Innovating Technology -Based Metadata Solutions for Improved Data Analysis

    Douglas Barta, CIO, PAREXEL International

    Real-Time Actionable Intelligence with a Solid Analytics Platform

    Rajeev Nair,

    right

    Individualizing Drug doses Amongst Patients of Depression

    By Apac CIO Outlook | Thursday, January 01, 1970
    Tweet

    Genetic variations can be responsible for the failure of drugs such as Serotonin reuptake inhibitors (SSRIs) which are used to treat depression. According to a new study published in the American Journal of Psychiatry, variations within genes and enzymes such as the CYP2C19 are responsible for differences in bioavailability of SSRIs like escitalopram amongst patients. Escitalopram’s dosage is prescribed to patients based on their specific genetic constitution, and this greatly improves therapeutic outcomes.

    SSRIs are commonly used for the treatment of depression, but several patients react and respond differently to them. Among all the SSRIs, escitalopram was quite frequently used in the clinics to treat patients with depression. But the use of this drug has become quite limited as the response to the drug was not as expected, with many patients developing adverse reactions after the discontinuation of treatment.

    To understand if a patient will be able to respond properly to a drug therapy, many researchers have been attempting to establish genetic biomarkers that can predict how a patient would respond. People with the variant of genes usually have increased enzyme expression and low blood levels of escitalopram. Studies show that one-third of the patients tested for drug levels have either too high or too low levels of drugs in their blood.

    Thus individualizing doses, genotyping of CYP2C19 could be of considerable clinical value and can give better all-round anti-depressive effect to a patient.

    Weekly Brief

    loading
    Top 10 Customer Relationship Management Consulting/Services Companies – 2020

    Featured Vendors

    Star Solutions

    Kareem Qureshi, MD & Sharada Balagopalan, Managing Partner

    ON THE DECK

    CRM 2020

    Top Vendors

    CRM 2019

    Top Vendors

    Previous Next

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    How Cognitive Computing Transforms Healthcare?

    How Cognitive Computing Transforms Healthcare?

    How to Establish Effective Cybersecurity Leadership in Post-COVID Era?

    How to Establish Effective Cybersecurity Leadership in Post-COVID Era?

    Disrupted Employees and Cybersecurity Risks

    Disrupted Employees and Cybersecurity Risks

    The Importance of Cognitive Analytics in Business Growth

    The Importance of Cognitive Analytics in Business Growth

    Why AI is Vital in Microservices Testing Automation

    Why AI is Vital in Microservices Testing Automation

    Three Key Trends in Cybersecurity

    Three Key Trends in Cybersecurity

    Loading...

    Copyright © 2021 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    |  Sitemap |  Subscribe

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/individualizing-drug-doses-amongst-patients-of-depression-nwid-4880.html